[Clinical experience with sustained release cefalexin (author's transl)]

Area of Science:

• Pharmacology
• Infectious Diseases

Background:

• Sustained-release cefalexin preparations (S-6436, S-6437) utilize a combination of non-enteric and enteric-coated granules.
• These formulations are designed for oral administration with a twice-daily (b.i.d.) dosing regimen.

Observation:

• The study involved 43 patients with skin/soft tissue infections and other infections.
• Patients received 1,000–2,000 mg/day (adults) or 20–50 mg/kg/day (children) in two divided doses.

Findings:

• Excellent efficacy was observed in 30 patients, with good efficacy in 13 others.
• The b.i.d. regimen was deemed useful in 11 patients.
• No adverse side effects were reported during the study.

Implications:

• S-6436 and S-6437 represent potentially valuable sustained-release cefalexin formulations.
• The b.i.d. dosing strategy appears effective and well-tolerated for treating infections.
• Further research may validate these preparations for broader clinical use.